This flu season has been comparatively mild so far, but public health experts warn it could intensify in the coming weeks after a new H3N2 subclade—identified after this season’s vaccine was manufactured—began circulating internationally. Data from the U.K. show unusually high hospitalisation rates for this time of year, and the variant (subclade K) was first detected in Australia near the end of its season before appearing in Japan and the United States. Authorities say the current vaccine still offers the best protection against severe illness, though effectiveness against infection appears reduced for the new subclade. Low vaccination coverage in some U.S. populations, including Virginia, compounds concern about a possible uptick in serious cases and pediatric harm.
Key takeaways
- Subclade K of H3N2 was first reported in Australia and has since been confirmed in Japan and the U.S.; U.K. surveillance links it to higher-than-typical hospitalisation rates for this season.
- U.K. data indicate current vaccines are about 32–39% effective at preventing infection overall, but roughly 72–75% effective in children, according to University of Virginia analysis.
- The U.S. CDC warned on Dec. 11 that circulation of a new H3N2 variant may reduce vaccine effectiveness, though vaccines remain protective against severe outcomes.
- Virginia’s vaccination coverage is low: roughly 28% overall, 20.6% among ages 5–17 and 39.8% for adults 50 and older, raising local vulnerability.
- Last season (2024–25) saw high severity across age groups, with an exceptionally high number of pediatric deaths; CDC data showed about 90% of those children were unvaccinated and 50% had no underlying conditions.
- Public-health guidance remains unchanged: vaccination for everyone 6 months and older, good hand hygiene, and staying home when ill to reduce spread.
Background
Influenza viruses evolve continuously; vaccine composition decisions are made months before the Northern Hemisphere season to allow time for production. That timing creates a window during which a new variant can emerge after vaccine strains are selected. In this cycle, subclade K of H3N2 was not dominant when manufacturers produced the vaccine, which helps explain the reduced match and the lower estimated protection against infection.
Last season’s severity—marked by unusually high paediatric mortality—heightened concern among clinicians and health departments. Public-health officials track several measures—virus detection, hospitalisations and deaths—to judge season severity. When vaccine uptake is low, community immunity weakens, increasing the chance a poorly matched variant will cause more hospitalisations and deaths. State departments, including Virginia’s, are urging vaccination and usual infection-control measures to blunt potential impact.
Main event
U.K. surveillance has recorded rising influenza hospitalisations this time of year, data officials say, and researchers there use the same vaccine strains as the United States, making their findings relevant to U.S. preparedness. University of Virginia experts summarised those data and estimated that the current vaccine prevents about 32–39% of infections overall but retains stronger protection—around 72–75%—in children. That pattern suggests vaccines may still reduce severe outcomes even if they are less effective at stopping infection.
Lisa Sollot, respiratory disease program coordinator for the Virginia Department of Health, noted subclade K was first observed in Australia late in that country’s season, then in Japan and the U.S. She said consecutive high-severity seasons are historically rare and that exact future severity is uncertain, but low vaccination coverage could amplify risks. Virginia’s current aggregated uptake across age groups is about 28%, with the adolescent group (5–17) particularly low at 20.6%.
Frederick G. Hayden, a professor at the University of Virginia School of Medicine and co-author of a Journal of the American Medical Association analysis, emphasised that subclade K is related to strains that contributed to the prior season’s severity. In a UVA release citing CDC findings, Hayden reiterated that available vaccines still reduce the risk of serious illness and may curb transmission, even if they are somewhat less effective against infection by the new variant.
The Centers for Disease Control and Prevention’s Dec. 11 report flagged acceleration of influenza activity in the United States, driven largely by A(H1N1) and H3N2 viruses, and warned that a new H3N2 variant might blunt vaccine protection somewhat. The CDC continues to recommend routine vaccination for everyone 6 months and older, citing strong evidence that vaccination lowers hospitalisation and death.
Analysis & implications
The immediate question for clinicians and hospitals is whether a rise in community cases will translate to a surge in severe cases and admissions. If vaccines remain moderately protective against severe disease—as existing estimates and prior-season experience suggest—the worst outcomes may be reduced, but health systems could still face higher demand for pediatric and adult inpatient care. Regions with low vaccination coverage are at higher risk of local strain on hospitals and outpatient services.
Public-health messaging must balance uncertainty with actionable advice: promote vaccination, reinforce hygiene, expand access to antivirals for high-risk patients, and encourage early care-seeking for severe symptoms. Antiviral medications are effective when given promptly and can reduce complications for vulnerable patients; clinicians should maintain a low threshold for prescribing for high-risk individuals during surge periods.
International spread—from Australia to Japan to the U.S.—illustrates the seasonal and global nature of influenza. Surveillance data from multiple countries help anticipate U.S. trends, but local factors (vaccination rates, population immunity, healthcare capacity) will determine regional impact. Monitoring hospitalisation rates, pediatric outcomes and vaccine effectiveness updates will be essential in coming weeks.
Comparison & data
| Measure | Reported value | Source context |
|---|---|---|
| Vaccine effectiveness (overall) | 32–39% | U.K. surveillance / UVA analysis |
| Vaccine effectiveness (children) | 72–75% | U.K. surveillance / UVA analysis |
| Virginia vaccination rate (all ages) | ~28% | Virginia Department of Health |
| Vaccination, ages 5–17 (VA) | 20.6% | Virginia Department of Health |
| Vaccination, ages 50+ (VA) | 39.8% | Virginia Department of Health |
The table summarises key figures cited by public-health officials and researchers. The relatively low overall vaccine effectiveness estimate reflects a mismatch between circulating subclade K and the vaccine strains selected months earlier. The much higher effectiveness in children is notable but does not eliminate risk, particularly where coverage among children is low. Officials will watch real-time hospitalisation and death counts to assess whether case increases translate into higher severity this season.
Reactions & quotes
UVA researchers and state health officials have expressed concern but emphasised vaccination as the primary defense against severe outcomes.
“Available vaccines will reduce the risk of serious illness and potentially the spread of this virus,”
Frederick G. Hayden, UVA School of Medicine
Hayden helped author a JAMA analysis of emerging surveillance and stressed that while the new variant likely reduces infection-prevention effectiveness, vaccines still lower severe disease risk. That distinction underpins current public-health recommendations.
“Low vaccination rates combined with subclade K’s emergence may potentially lead to a severe season, but we really can’t say exactly how severe,”
Lisa Sollot, Virginia Department of Health
Sollot highlighted local vaccination gaps—particularly among school-age children—and urged standard prevention steps: vaccination, handwashing and staying home when ill. Her remarks reflect concerns about pediatric vulnerability observed last season.
“We are seeing circulation of a new variant of H3N2 virus for which our vaccines may be somewhat less effective,”
Centers for Disease Control and Prevention (Dec. 11 report)
The CDC’s Dec. 11 communication signalled accelerating influenza activity in the U.S. and recommended maintaining current immunisation and treatment strategies while monitoring variant impact.
Unconfirmed
- Exact severity trajectory: researchers cannot yet predict how much worse the season will be, or whether hospitalisations will exceed last season’s peaks.
- Degree of vaccine protection against hospitalisation specifically for subclade K remains under study; current estimates focus on infection prevention and pediatric effectiveness.
- Geographic spread patterns within the U.S. and timing of peak activity are uncertain and may vary regionally.
Bottom line
The emergence of H3N2 subclade K raises a credible risk that the 2024–25 influenza season could intensify in coming weeks, particularly in communities with low vaccine uptake. Although current vaccines appear less effective at preventing infection with this variant, available evidence indicates they still reduce severe illness, hospitalisation and death—especially in children where the vaccine retains stronger effectiveness.
Public-health priorities are clear: increase vaccination coverage (everyone 6 months and older), encourage early treatment for high-risk patients, and maintain nonpharmaceutical measures such as hand hygiene and staying home when ill. Close monitoring of hospitalisation, pediatric outcomes and updated vaccine-effectiveness estimates will determine whether emergency responses or surge planning are required.
Sources
- The Seattle Times (news)
- The Virginian-Pilot (news) — original reporting from Norfolk, Va.
- Centers for Disease Control and Prevention (official) — Dec. 11 communication and weekly surveillance updates
- NHS England (official) — hospitalization and surveillance data referenced in U.K. reports
- University of Virginia School of Medicine (academic) — analysis and expert commentary